Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | SVP, Chief Technology Officer | July 26, 2019 | July 30, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date July 26, 2019 · Filed July 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,853 |
Reported balance
After 2019-07-26 transaction · row 1
1 source rowRow 1 · 2019-07-26 · Exercise / conversion · Acquired 5,197 · Balance 127,853 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2028-04-12 | Direct | 10,396 |
Reported balance
After 2019-07-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-26 · Exercise / conversion · Disposed 5,197 · Balance 10,396 F1: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 26, 2019 Filed Jul 30, 2019 23:20 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 5,197 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-19-015483 · doc1.xml · derivative · entry 2 Hager Jeffrey · CIK 0001777424 · SVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,396 Underlying: Common Stock · 5,197 shares Expires 2028-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 23:20 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 5,197 | $4.31 | $22,399.07 |
DisclosureSEC source: 0001567619-19-015483 · doc1.xml · nonDerivative · entry 1 Hager Jeffrey · CIK 0001777424 · SVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2019 Filed Jul 26, 2019 16:50 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 7,145 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-19-015228 · doc1.xml · derivative · entry 4 Hager Jeffrey · CIK 0001777424 · SVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,275 Underlying: Common Stock · 7,145 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 10, 2019 Filed Jul 26, 2019 16:50 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 7,145 | $4.31 | $30,794.95 |
DisclosureSEC source: 0001567619-19-015228 · doc1.xml · nonDerivative · entry 2 Hager Jeffrey · CIK 0001777424 · SVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,656 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jul 26, 2019 16:50 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 8,628 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-19-015228 · doc1.xml · derivative · entry 3 Hager Jeffrey · CIK 0001777424 · SVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,420 Underlying: Common Stock · 8,628 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 19, 2019 Filed Jul 26, 2019 16:50 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 8,628 | $4.31 | $37,186.68 |
DisclosureSEC source: 0001567619-19-015228 · doc1.xml · nonDerivative · entry 1 Hager Jeffrey · CIK 0001777424 · SVP, Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.